Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy in India
NCT07004972Phase 4Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2025
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mavacamten in hypertrophic cardiomyopathy (HCM), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence of serious Treatment Emergent Adverse Events at 48 weeks. Started Sep 2025; status: active, not recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT07004972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07004972.